Vaccines for mucosal immunity to combat emerging infectious diseases. by van Ginkel, F. W. et al.
123
Synopses
Vol. 6, No. 2, March–April 2000 Emerging Infectious Diseases
Behavioral changes in the human host may
be contributing to the emergence of new diseases.
Perhaps emerging pathogens become resistant to
antibiotics or (through genetic recombination)
become more resistant to host defenses.
Recombination events or lack of exposure can
result in loss of immunity of the population to the
pathogen, as has been well documented with
influenza virus. Recombination events increase
the infection rate by the emerging pathogen and,
in the case of influenza virus, occasionally result in
pandemics. A large number of emerging pathogens
are mucosally transmitted and must cross mucosal
barriers to infect the host. Thus, our ultimate
defense against new and reemerging infectious
disease will require effective mucosal vaccines.
Mucosal surfaces are prominent in the
gastrointestinal, urogenital, and respiratory
tracts and provide portals of entry for pathogens.
Increased sanitation and hygiene, the use of
antibiotics, and childhood vaccination have
enormously decreased the death rate from
infectious diseases over the last century (1). Thus,
infectious agents not controlled by antibiotics and
improved sanitation and hygiene measures
would most likely be prevalent under current
conditions. Pathogens in this category include
respiratory viruses, for example, influenza virus.
Another group includes sexually transmitted
disease (STD) pathogens, for example, HIV. The
fact that a) pneumonia and influenza virus and b)
HIV infection were listed as the leading causes of
death (ranked number 6 and 8, respectively) by
infectious agents in the United States  in 1997
confirms this notion (1). However, other viral and
bacterial STDs are of major concern.
The best defense against these predomi-
nantly mucosal pathogens would be vaccines,
preferably mucosal vaccines capable of inducing
both systemic and mucosal immunity. Although
numerous strategies exist for the induction of
mucosal immune responses, we will focus on the
use of live attenuated vectors, such as Salmonella
typhi and adenovirus. In a recent National
Institutes of Health news release (April 8, 1999)
from the Institute of Medicine report on domestic
vaccine priorities for the future, which compared
costs and health benefits, influenza was listed as
one of seven diseases requiring an effective
vaccine. The induction of protective mucosal
immunity to influenza virus has made consider-
able progress with the development of cold-
adapted influenza strains, which are in phase-3
clinical trials. Mucosal immunity, which is
important for long-term protection, forms a first
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The mucosal immune system consists of molecules, cells, and organized lymphoid
structures intended to provide immunity to pathogens that impinge upon mucosal
surfaces. Mucosal infection by intracellular pathogens results in the induction of cell-
mediated immunity, as manifested by CD4-positive (CD4+) T helper-type 1 cells, as well
as CD8+ cytotoxic T-lymphocytes. These responses are normally accompanied by the
synthesis of secretory immunoglobulin A (S-IgA) antibodies, which provide an important
first line of defense against invasion of deeper tissues by these pathogens. New-
generation live, attenuated viral vaccines, such as the cold-adapted, recombinant nasal
influenza and oral rotavirus vaccines, optimize this form of mucosal immune protection.
Despite these advances, new and reemerging infectious diseases are tipping the balance
in favor of the parasite; continued mucosal vaccine development will be needed to
effectively combat these new threats.Synopses
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Figure 1. M cells and the induction of mucosal immunity. M cells are present in mucosal inductive sites in both
the intestinal and upper respiratory tract, specifically in Peyer’s patches and the nasal-associated lymphoid
tissue, the tonsils and adenoids. M cells are thought to play an important role in antigen processing and possibly
the induction of antigen-specific mucosal immunity in mucosal effector sites. Tissues followed by question marks
are presumed sites since limited data are available on these tissues.
line of defense against mucosally transmitted
pathogens such as influenza. Mucosal defense
against pathogens consists of both innate
barriers, such as mucous, epithelium, and innate
immune mechanisms, and adaptive host immunity,
which at mucosal surfaces consists predominantly
of CD4+ T cells, secretory immunoglobulin A (S-
IgA), and antigen-specific cytotoxic T-lymphocytes
(CTLs). This review will focus on the antigen-
specific mucosal immune system.
Emerging Pathogens
The major obstacle in combating emerging
infectious diseases is the lack of more effective
antibiotics and vaccines. Misuse of antibiotics has
led to antibiotic-resistant pathogens, further
intensifying the need for mucosal vaccine
development—a cost-effective disease-preven-
tion tool. The Department of Vaccines and Other
Biologicals within the World Health Organiza-
tion (WHO) has defined several priority vaccines
for accelerated introduction; they include
pneumococcal,  Haemophilus influenzae type b,
rotavirus, and hepatitis B. Other vaccine goals
within WHO are eradication of polio, reduction of
measles cases by 90%, and elimination of
neonatal tetanus (2). For most pathogens targeted
by WHO for vaccines, induction of mucosal
immunity appears most appropriate based on the
routes of infection. Thus, a better understanding
of the mucosal immune system is needed before
effective mucosal vaccines can be developed.
The Mucosal Immune System
Mucosal inductive sites in humans, such as
the Peyers patches in the intestinal tract and the
nasal-associated lymphoreticular tissue in the
oropharyngeal cavity, stand as sentinels to the
intestinal and respiratory tracts and represent
the major sites where mucosal immune responses
are initiated (Figure 1). Common features of
these inductive sites are microfold or M cells.125
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Figure 2. Differentiation and regula-
tion of T-helper subsets and the
immune response in the mucosal
compartments. Encounter of patho-
gen-derived antigen or vaccine anti-
gen will stimulate T-helper cells to
secrete cytokines. Depending on the
stimulus, a Th1 or Th2 cell response is
induced. For example, intracellular
pathogens will induce production of
IL-12/IL-18 by macrophages, activat-
ing IFN-γ ð production by NK cells and
inducing differentiation to a Th1-
mediated immune response, which
supports CMI and production of
complement-fixing antibodies, pre-
sumably by production of cytokines
such as IFN-γ ð, IL-2, and TNF-β ð. A
Th2 response can be observed upon
infection with parasites or upon
vaccine administration; this response
is characterized by production of
cytokines such as IL-4, IL-5, IL-6, IL-
10, IL-13 which support humoral
immunity. However, for induction of a
S-IgA, TGF-β ð1 is required to enable B
cells to switch to IgA. TGF-β ð1
production is associated with inhibi-
tion of IL-4 production by Th2 cells
inhibiting IgE production.
Although the precise function of M cells has not
yet been established, recent studies indicate that
they are involved in uptake, transport, processing,
and possibly presentation of microbial antigens
(3,4). The interaction of epithelial cells with T and
B lymphocytes induces epithelial cells to
differentiate into M cells in vitro (5), indicating
the importance of lymphocyte-epithelial cell
interactions for maintaining M cells in the
follicle-associated epithelium of the Peyer’s
patches. These lymphocyte- M cell interactions
can occur in the pocket of the M cells and are
mediated through thin cellular extensions,
indicating that cell-cell interactions are an
intricate part of the M-cell function and that they
may facilitate transfer of luminal antigens,
viruses, bacteria, and other protein components (3).
The ability of the M cell to transport particulates
from the lumen across the epithelial barrier has
been exploited by some pathogens to facilitate
entry into the host, as has been demonstrated for
invasive strains of Salmonella (6) and reovirus (7)
(Figure 1). Identification of bacterial and viral
virulence factors associated with targeting M
cells, such as the sigma protein from reovirus,
may allow development of mucosal vaccines and
vectors to deliver vaccine components directly
into mucosal inductive sites.
T-Cell and Cytokine Involvement in
B-Cell Isotype Commitment to IgA
Although the variables involved in the
switching of B cells to polymeric IgA (pIgA)-
producing plasma cells have been studied, many
questions remain. In recent years, gene-deleted
or knockout mice have contributed to a better
understanding of the role of specific cells,
cytokines, and surface molecules involved in IgA
isotype switching. Presumably, isotype switching
occurs in mucosal inductive sites, while IgA
production by plasma cells occurs in mucosal
effector sites, separating the IgA switching and
IgA secretion by B cells into different immune
compartments (8). Each of these stages requires
specific signals, such as costimulatory molecules,
cytokines, and T-helper cells, to give rise to antigen-
specific S-IgA Abs in mucosal effector sites.
Neither Th1- nor Th2-type cytokines contrib-
uted significantly to the switching of B cells to
surface IgA positive (sIgA+) B cells (Figure 2).Synopses
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This process required the presence of transform-
ing growth factor β ð1 (TGF−β ð1), which can
activate the switch of B cells to the IgA isotype (9).
TGF-β ð1 induces a small proportion (<2%) of B
cells to switch to IgA in activated B-cell
cultures  (9,10). However, TGF-β ð1, when used in
combination with additional signals, increased
TGF-β ð1-induced switching in 10% to 20% of B
cells and approached IgA+ B-cell levels observed
in Peyer’s patches (11). Thus, multiple activation
signals contribute to the switch to IgA, i.e., B-cell
activation by cross-linking the B-cell antigen
receptor, CD40-CD40L interactions to promote
switching, TGF-β ð1 by directing the switch to
IgA, and Th2-type cytokines by increasing the
number of post-switch IgA+ B cells and their
differentiation into IgA-secreting plasma cells. In
addition, activated T cells and dendritic cells from
the Peyer’s patches were more effective in
switching sIgM+ sIgA- B cells to IgA-producing
cells than were T cells and dendritic cells derived
from the spleen (12). This suggests that mucosal
inductive sites contain specialized T cells or
dendritic cells beneficial for B cells to
differentiate into IgA-producing cells.
T-cell helper functions play important roles in
generating antigen-specific humoral and cell-
mediated immunity in both systemic and mucosal
compartments. The importance of CD4+ T cells
for generating protective immunity is illustrated
by the lack of these cells in AIDS patients. The
differentiation of Th0 cells into either Th1 or Th2
is driven by cytokines such as interleukin 12
(IL-12), interferon γ ð (IFN-γ ð), and IL-4,
respectively. For example, intracellular patho-
gens, such as viruses and intracellular bacteria,
induce production of IL-12 or IL-18 by activated
macrophages, presumably after ingestion of the
particulate pathogen, inducing IFN-γ ð produc-
tion in natural killer (NK) cells, which in turn
drives the differentiation of Th0 cells toward a
Th1 phenotype producing IFN-γ ð, IL-2, and
tumor necrosis factor β ð (TNF-β ð)ð (Figure 2).
Murine Th1-type responses are associated with cell-
mediated immunity, such as delayed-type
hypersensitivity and IgG2a antibody responses (8).
Th0 cells are differentiated into Th2-type cells
when soluble exogenous antigen is administered,
triggering CD4+, NK1.1+ T cells to produce IL-4.
The Th2 cell produces more IL-4, expanding Th2-
cells, which support the associated immune
response. Th2 cells secrete cytokines such as
IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. The
production of IL-4 supports IgG1 subclass and
IgE production, but other antibodies such as
IgG2b and IgA, are also produced during a Th2-
dominated response (8).
It is not known whether Th1 or Th2 cells are
beneficial for optimal S-IgA production. Histori-
cally, Th2-type cytokines were considered major
helpers for antibody responses. For example,
S-IgA Ab responses were supported by mucosal
adjuvants such as cholera toxin, which induced
polarized Th2 cell responses (13). However, S-IgA
Ab responses may also be induced through Th1-
dominated responses, as observed with intracel-
lular pathogens such as Salmonella in the
gastrointestinal tract (14) or influenza virus in
the upper respiratory tract (15). Thus, either Th1
or Th2 cells or a combination of these cell types
can support antigen-specific S-IgA Ab responses.
In this respect, Th2-type cytokines play a role in
terminal differentiation of B cells, that are
already committed to IgA (16-18), while the Th1-
type cytokine IFN-γ ð has been implicated in the
induction of the polymeric Ig receptor (pIgR)
needed for transport of S-IgA (19). Cross-
inhibition of Th1 and Th2 cell-directed IgG2a and
IgE production was mediated through IFN-γ ð and
IL-4, respectively (Figure 2) (20,21).
Mucosal S-IgA Antibody Responses
The hallmark of the mucosal immune system
is the production of S-IgA. S-IgA results from
transcytosis of pIgA across the epithelium
through binding to the pIgR. S-IgA is released
from the pIgR by cleavage of the receptor,
resulting in pIgA covalently associated with a
substantial part of the pIgR, i.e., the secretory
component (22). This complex, referred to as
S-IgA, seems to be more resistant to proteolysis in
external secretions. Additional roles for S-IgA in
protection are suggested by its reduction of
influenza virus attachment and its prevention of
internalization of virus into baby hamster kidney
cells. In contrast, the action of monomeric IgA is
indistinguishable from that reported for IgG and
is less efficient than S-IgA for inhibition of
influenza virus entry (23). In addition, pIgA, as
opposed to IgG or monomeric IgA, neutralizes
virus intracellularly, as first was shown with
Sendai virus (24). Furthermore, transport of pIgA
containing immune complexes across epithelial
cells expressing the pIgR is another defense
mechanism of the mucosal immune system
against pathogen entry (25).127
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Figure 3. Pathways of
intracellular pathogen
clearance from infected
cells by cytotoxic cells.
Intracellular pathogen-de-
rived antigens complexed
to MHC class I molecules
are recognized by CTLs,
while NK cells recognize
the absence or suppressed
levels of MHC class I
molecules on infected cells.
Activated cytotoxic cells
deliver apoptotic signals
through Fas ligand and
perforin to infected cells.
They also secrete cytokines
(IFN-γ ð, TNF-α ð) and
chemokines (Rantes, MIP-
1α ð, MIP-1β ð) to inhibit or
suppress intracellular
pathogen replication.
These characteristics of pIgA are beneficial in
preventing infection and inflammation at
epithelial surfaces. The transport of pIgA across
epithelial cells allows active elimination of
immune complexes at mucosal sites and even
virus inside epithelial cells. Evidence that these
observations were not an artifact of the in vitro
system was provided by the murine backpack
model of rotavirus-specific monoclonal antibodies
(mAb) to VP4 and VP6 proteins. In this model,
nonneutralizing VP6-specific IgA mAb were
protective, but not when administered directly to
the gastrointestinal tract, indicating that IgA
transcytosis played a prominent role in
effective immune exclusion (26). Thus, virus-
specific, intra-epithelial IgA can inhibit viral
entry and replication.
Cell-Mediated Immunity
at Mucosal Surfaces
Although S-IgA has been shown to be an
important effector molecule to protect mucosal
surfaces, the contribution to mucosal protection
by the cellular immune system should not be
underestimated. The strategic advantage of cell-
mediated versus antibody-mediated immune
responses is that T cells can recognize peptides
derived from core proteins of the pathogen, such
as influenza virus. Core proteins are usually
expressed and presented much earlier during
infection than proteins targeted for neutralizing
antibodies, such as HA and NA of influenza virus.
Subsequently, cell-mediated immunity (CMI)
occurs before the induction of antibodies and
forms an early line of defense. Although
antibodies to core proteins are also formed later
in the immune response, their exact role in
protective immunity is not clear. Besides
supporting humoral immunity, CD4+ T-helper
cells function in CMI as producers of cytokines,
which mediate delayed-type hypersensitivity and
support CTLs and which as such are critical
components of the CMI responses to intracellular
pathogens. For example, major histocompatibil-
ity complex (MHC)-restricted CTL responses are
supported by Th1 cells. Cytotoxic cells can be
classified based on antigen specificity and MHC
restriction, i.e., nonspecific cytotoxic cells and
antigen-specific, MHC-restricted CTLs. The first
kind is composed of various cell types, including
NK cells and antibody-dependent cytotoxicity,
and functions very early in the immune response
(day 1 to 3), and these cells are detected
throughout the mucosal immune system. Pre-
sumably, they decrease pathogen load in the
early stage of the immune responses, while
antigen-specific responses are still being
established. The second type, antigen-specific
CTL, achieved optimal activity a little later
than nonspecific CTL, i.e., at day 3 to 5 of the
immune response before antibody production.
Both antigen-specific and nonspecific cyto-
toxic cell types can control growth of intracellular
pathogens by two distinct mechanisms (Figure 3).Synopses
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First, they can respond to the infection by
secreting a number of cytokines such as IFN-γ ð
and TNF-α ð (27) or chemokines such as Rantes,
macrophage-inflammatory protein-1α ð (MIP-
1α ð)ð, and MIP-1β ð (28,29). These soluble factors
inhibit growth of intracellular pathogens such as
viruses without destroying the host cell. Second,
cytotoxic cells can effectively and efficiently
recognize and lyse infected cells and prevent
multiplication of viruses. Little is known about
the induction, compartmentalization, and hom-
ing pattern of cytotoxic cells. Their presence in
the mucosal compartment upon infection reflects
their importance for protection against patho-
gens at mucosal surfaces.
Antigen-Specific CTLs
CTLs play an important role in the
elimination of cells infected with various
intracellular pathogens by recognizing pathogen-
specific antigen/MHC complexes. Antigen-spe-
cific CTLs inhibit further spread of pathogens
and help to terminate infections. Compartmen-
talization of pathogen-specific CTL responses
has been reported and located at the site of
initial infection. For example, CTLs preferen-
tially  compartmentalize in mucosa-associated
lymphoreticular tissues after pulmonary or
intestinal infection.
CTLs in the Intestinal Tract
Presentation of rotavirus by the intestinal
mucosal surface was not required for induction of
virus-specific cytotoxic intra-epithelial lympho-
cytes in the intestinal tract (30). In addition, the
site at which rotavirus is first presented to the
immune system will determine the site where
rotavirus-specific CTL precursors (pCTL) first
appear; however, regardless of the route of
inoculation, rotavirus-specific pCTL can be found
throughout the lymphoid system 21 days after
the initial infection (31). Adoptive transfer of
splenic lymphocytes from immunized animals
protected suckling mice against murine rotavirus-
induced gastroenteritis in the absence of
rotavirus-specific neutralizing antibodies, indi-
cating that antigen-specific CTLs protect against
mucosal pathogens in the intestinal tract (32).
Thus, thymus-derived α ðβ ð T cells can migrate to
the intestinal epithelium after antigen-specific
activation and protect the host against subse-
quent challenge. This notion is supported by
findings that systemic immunization with
attenuated macaque-specific Simian immunode-
ficiency virus induced virus-specific CTL responses
in gut-associated lymph nodes and limited
superinfection following mucosal challenge (33).
CTLs in the Respiratory
and Urogenital Tracts
The distribution of CTLs following influenza
virus infection in different mucosal compart-
ments indicates that lymph nodes draining
mucosal surfaces function as reservoirs for
memory T cells. Mediastinal lymph nodes, the
draining lymph nodes of the lungs, are considered
the site where antigen presentation to T cells
initially occurs before clonal expansion. Subse-
quently, T cells migrate to effector sites
(mesenchyma of the lungs and airways) to
interact with infected cells (34,35). Thus,
compartmentalization of memory CTL responses
to mucosa-associated lymphoreticular tissue may
be related to the initial site of virus infection. This
notion was confirmed by the observation that
induction of protective antiviral memory CTL in
mucosal tissues depends on region-specific
mucosal immunization (36). HIV-specific CTL
have been detected in the cervix (37) or semen (38)
of HIV-infected persons. These studies indicate
that the initial site of antigen exposure and
induction of antigen-specific CTL responses in
the urogenital tract are associated. Further
evidence for this notion comes from the use of
MHC class 1 tetramer technology, by which
antigen-specific quantitation of CD8+ T cells can
be performed. Upon intranasal influenza admin-
istration, most antigen-specific, IFN-γ ð-produc-
ing effector CD8+ T cells were located in bronchial
lavages and both effector (eCTL) and memory
CTL (mCTL) occurred at a much higher frequency
than initially thought based on limiting dilution
assays (39). Since respiratory virus infection
induces enlargement of the mediastinal lymph
nodes early in the immune response and since
these lymph nodes contain a relative small
number of mCTL after initial exposure, a strong
recruitment from circulating T cells occurs, or
alternatively, clonal expansion of the resident
mCTL takes place (39).
The presence of CTLs in mucosal
compartments may contribute to the control of,
and recovery from, infection by intracellular
pathogens at mucosal surfaces. Since different
pathogens have distinct infection routes or different
localization in the host, compartmentalization of129
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protective, antigen-specific CTLs may vary,
based on the specific pathogen. In general,
mucosal infection induces primarily antigen-
specific CTLs in the mucosal compartment and
mucosa-associated lymphoid organs to control
pathogens at the portal of entry, i.e., the
mucosal surfaces.
The Common Mucosal Immune System
Antigenic exposure at mucosal sites activates
mucosal B and T-lymphocytes to emigrate from
the inductive site and home to various mucosal
effector sites. The common mucosal immune
system involves homing of antigen-specific
lymphocytes to mucosal effector sites other than
the site where initial antigen exposure occurred.
This pathway has almost exclusively been
documented for S-IgA antibody responses at
mucosal surfaces mediated by B cells, but similar
events are assumed to take place with T cells.
Different immunization routes, such as oral,
rectal, and intranasal, can induce generalized
mucosal immune responses. However, oral
immunization induced a more restricted mucosal
response, as reflected by a more restricted homing
receptor profile than nasal immunization. Specifi-
cally, after systemic immunization the predomi-
nant homing receptor on antibody secreting cells
is the L selectin, after oral immunization the
α ð4β ð7 integrin, and after nasal immunization a
large portion expressed both the L selectin and
the  α ð4β ð7 integrin. The fact that nasal
immunization induced antibodies in a broader
range of tissues, such as saliva and the urogenital
tract, than oral immunization reflects the more
restricted nature of oral immunization (8).
Circumstantial evidence indicates the exist-
ence of a common mucosal immune system for
cell-mediated immunity (44). The data available
indicate that antigen-specific CTL responses at
mucosal surfaces are dictated by induction of CTL
locally and are not due to migration from distant
sites. CTL do normally migrate to the systemic
compartment. It could be hypothesized that the
presence of antigen-specific CTL in the systemic
compartment would allow for quick, protective
responses at any mucosal site, but more research
is needed to confirm this hypothesis. Such
research is crucial, since limited CTL activity at
mucosal surfaces could be a built-in mechanism
to protect the mucosal epithelium from damage, a
notion supported by the observation that pCTL in
immunologically privileged sites fail to differenti-
ate into fully functional CTL, unless exposed to
antigen (40). This concept could have a major
influence on future vaccine development. If
mucosal antigen-specific memmory CTL re-
sponses are observed only after mucosal
immunization, optimal protection against patho-
gens would require the use of mucosal vaccine.
However, systemically induced CTL can generate
an antigen-specific mucosal CTL response; in
addition, systemic immunization can be used for
cell-mediated protection at mucosal surfaces.
Mucosal Vaccines
Although mucosal application of vaccines is
attractive for many reasons, only a few mucosal
vaccines, mostly oral, have been approved for
human use. These vaccines include poliovirus,
Salmonella typhi, and the recently approved
tetravalent rotavirus vaccine, RotaShield, con-
sisting of reassorted rhesus-human rotaviruses.
The latter vaccine has recently been associated
with intussusception, a type of bowel obstruction,
and its use has been suspended to await a more
detailed analysis of this major problem. Human
approved mucosal vaccines so far involve live
attenuated pathogens, and for this reason oral
poliovirus vaccine is recommended after receiv-
ing the injected inactivated virus, since a limited
number of polio cases occur after immunization
with the live attenuated virus. Since the live virus
induces better, longer-lasting protection, it is
given after some level of systemic immunity has
been achieved, to limit possible problems.
Another oral vaccine is the typhoid fever vaccine,
which consists of attenuated S. typhi strain
Ty21a. The cold-adapted influenza virus (CAIV),
which is in advanced clinical trials, is the first
mucosal vaccine given nasally to humans and has
been shown to generate protective immune
responses (41). Thus, CAIV are promising
vehicles for generating protective immunity to
influenza in children. The use of CAIV may also
resolve some of the problems observed during the
recent outbreak of the Hong Kong virus. Due to
its relatedness with A/Chicken/Hong Kong/258/
97 (H5N1) virus, the production of this virus for
vaccine purposes was severely hampered because
of its lethal effect on chicken eggs. The use of
CAIV, which is readily produced by reassortment,
might overcome this problem and allow
production of high-titer virus for vaccine purposes.
An alternative approach is the use of DNA
vaccines. Plasmid DNA was used in clinical trialsSynopses
Emerging Infectious Diseases Vol. 6, No. 2, March–April 2000 130
to induce protection against several pathogens,
including hepatitis B virus, herpes simplex virus,
HIV, malaria, and influenza (42). However, in all
cases induction of antibodies and CTL in the
systemic but not the mucosal compartment was
reported. Although some progress has been
made in inducing mucosal immunity in
laboratory animals with DNA vaccines by using
cationic lipids or other delivery vehicles, as well
as immunostimulatory CpG dinucleotide mo-
tifs, no reports exist on the induction of mucosal
immunity by DNA vaccines in humans.
Unmethylated CpG dinucleotides are immuno-
stimulatory, especially when presented in a 6
base-pair motif in which the central CpG is
flanked by two 5' purines and two 3'
pyrimidines.
Another promising avenue for mucosal
vaccines is the use of bacterial adhesins. Mucosal
antibodies to these proteins block the pathogen’s
ability to penetrate mucosal barriers. Adhesins
are very attractive options because of the highly
conserved nature of these proteins due to their
association with conserved host receptor pro-
teins. The pilus-associated adhesin FimH from
uropathogenic  E. coli binding to mannose-
oligosaccharides is a vaccine target. Mucosally
administered vaccines containing FimH are in
clinical trials that will assess their efficacy
compared with parenterally administered vac-
cines. Furthermore, the recently approved
acellular pertussis vaccine also contains adhesins,
i.e., the filamentous hemagglutinin and pertactin,
which recognize sulphated sugars on
glycoconjugates and the integrin-binding protein
motif Arg-Gly-Asp, respectively. This indicates
that adhesin-specific immunity might be a
successful approach for generating mucosal
protection against pathogens (43). The impor-
tance of blocking the initial attachment and entry
into the host cell has been recognized for some
time for viruses such as influenza, but the use of
this approach for bacteria, still in its infancy, has
enormous potential for mucosal vaccines.
Future Directions
The mucosal immune system is a complex
and redundant system that generates large
amounts S-IgA as well as cell-mediated immunity
at mucosal surfaces to prevent pathogen
infiltration and inflammation. The mucosal
immune system should be most efficient in
providing protection against pathogens and
generating longer-lasting protection through
using attenuated pathogens for vaccines pur-
poses. The only mucosal vaccines approved for
humans are attenuated pathogens. Future
mucosal vaccines will also involve vaccine
strategies other than attenuated pathogens. For
example, DNA vaccines or subunit vaccines, such
as bacterial adhesins, in combination with potent
mucosal adjuvants (such as QS-21, a saponin
derived from the bark of the South American tree
Quillaja saponia Molina, mutant enterotoxins,
unmethylated CpG motifs, or cytokines such as
IL-12) or mucosal delivery systems, such as
microspheres, will have the potential to be the
next generation of vaccines inducing mucosal
protection to pathogens in humans.
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